BRISBANE, Calif. / Aug 21, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in a fireside chat at the Wells Fargo Healthcare Conference in Boston,... Read More

BRISBANE, Calif. / Aug 06, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial... Read More

Grew Testing Services Volume to Approximately 49,500, Increase of 13% Year-Over-Year AlloSure Kidney Testing Volumes Grew Nearly 20% Year-Over-Year Narrows Full Year 2025 Revenue Guidance to $367 Million to $373 Million BRISBANE, Calif. / Aug 06, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company - a leading precision medicine company focused on the discovery, development and commercialization of... Read More

KOAR, the Largest Prospective Study of Its Kind, Demonstrates Clinical Utility of AlloSure® in Kidney Transplant Surveillance AlloSure Kidney dd-cfDNA Elevation Strongly Predicts Rejection and Improves Biopsy Yield BRISBANE, Calif. / Aug 06, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of... Read More

Announces the Launch of AlloSure® Plus Integrated into EPIC Aura BRISBANE, Calif. / Jul 31, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the presentation of several high-impact... Read More

BRISBANE, Calif. / Jul 23, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. Company management will host a... Read More

Draft Policy Recognizes the Importance of Surveillance Testing for Early Detection of Allograft Rejection in Kidney, Heart, and Lung BRISBANE, Calif. / Jul 18, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and... Read More

Board of Directors Authorizes New $50 Million Share Repurchase Program BRISBANE, Calif. / Jun 03, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the... Read More

BRISBANE, Calif. / May 13, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences. Craig-Hallum 22 nd Annual... Read More

First Quarter Revenue of $84.7 Million, Increased 18% Year-Over-Year Grew Testing Services Volume to Approximately 47,100, Marking Seventh Consecutive Quarter of Sequential Testing Services Volume Growth BRISBANE, Calif. / Apr 30, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights Reported first quarter revenue of... Read More

Findings from ALAMO Study Show AlloSure Lung is Associated with Prognosis of Chronic Lung Allograft Dysfunction and Restrictive Allograft Syndrome AlloSure Lung Surveillance Monitoring Identifies the Onset of Acute Cellular Rejection and Treatment Response BRISBANE, Calif. / Apr 29, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery,... Read More

Breadth of Data Demonstrates Growing Real-World Adoption and Clinical Importance of CareDx Testing Solutions in Heart and Lung Transplant Patient Management New SHORE Study Findings Demonstrate that HeartCare is Prognostic of Long-Term Outcomes and Informs Treatment Decisions BRISBANE, Calif. / Apr 24, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused... Read More

BRISBANE, Calif. / Apr 21, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ (“CareDx” or the “Company”)— a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 7, 2025, CareDx granted to Jennifer Foley, the Company’s newly... Read More

BRISBANE, Calif. / Apr 08, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a... Read More

AlloSure Heart is Now Validated and Commercially Available for Pediatric Heart Transplant Patients Under 15 AlloSure Kidney is Now Validated and Commercially Available for Simultaneous Pancreas-Kidney Transplant Patients BRISBANE, Calif. / Mar 11, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of... Read More

Full Year 2024 Revenue Grew 19% to $334 Million Expects Full Year 2025 Revenue of $365 Million to $375 Million BRISBANE, Calif. / Feb 26, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter Financial Highlights Revenue of $86.6 million, increased 32% year-over-year Testing services revenue of $63.8 million, increased... Read More

All Patent Claims Asserted Against CareDx are Found to Be Invalid BRISBANE, Calif. / Feb 25, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the District Court overturned the jury verdict in patent litigation... Read More

AlloSeq cfDNA Consistent with Performance of Proven AlloSure Testing CareDx Brings Innovative Non-Invasive Transplant Monitoring to Patients Internationally with AlloSeq cfDNA BRISBANE, Calif. / Feb 20, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value... Read More

New Data from the ACROBAT Study Shows AlloHeme Detects Cancer Relapse with Clinically Meaningful Lead Time BRISBANE, Calif. / Feb 13, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today... Read More

BRISBANE, Calif. / Feb 11, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, February 26, 2025. Company... Read More

Fourth Quarter Revenue is Expected to Increase 30% Year-Over-Year Expects Full Year 2024 Revenue of $332 Million to $333 Million BRISBANE, Calif. / Jan 13, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Financial Results Revenue is expected to be... Read More

BRISBANE, Calif. / Dec 18, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San... Read More

CareDx Continues Strategic Expansion into Hematology Oncology with Pharmacokinetic and Monitoring Assays for Cell Therapy Patients BRISBANE, Calif. / Dec 11, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and... Read More

BRISBANE, Calif. / Nov 12, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences. Jefferies London Healthcare... Read More

BRISBANE, Calif. / Nov 04, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Total revenue of $82.9 million increased 23% year-over-year Testing Services volume of 44,600 tests increased 16% year-over-year GAAP net loss of $7.4 million, non-GAAP net income of $8.0 million, and positive adjusted EBITDA... Read More

Partnership Includes Early Access Program Enabling HLA Labs to be at the Forefront of Innovative Solutions for Donor-Recipient Matching New Data at Annual American Society for Histocompatibility and Immunogenetics Meeting Shows AlloSeq and LinkPrep Technology Enables High-Resolution Genotyping and Haplotyping without Family Studies BRISBANE, Calif. & SCOTTS VALLEY, Calif. / Oct 23, 2024 / Business Wire / CareDx, Inc.... Read More

New Data Highlights Latest Advancements to AlloSeq Tx Used in Solid Organ and Stem Cell Transplant HLA Typing CareDx Introduces Newest Enhancements to QTYPE for Rapid Deceased Donor HLA Typing BRISBANE, Calif. / Oct 21, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated,... Read More

Third Quarter 2024 Financial Results to be Reported on November 4, 2024 BRISBANE, Calif. / Oct 15, 2024 / Business Wire / CareDx, Inc . (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for... Read More

BRISBANE, Calif. / Oct 11, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on October 8, 2024, CareDx granted to Jing Huang, the Company’s newly appointed Chief Data and AI... Read More

BRISBANE, Calif. / Oct 09, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence... Read More

BRISBANE, Calif. / Oct 08, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the Company will be hosting an Investor Day on October 15, 2024, in New York City, New York, starting at... Read More

DOJ Concludes Investigation and Declines to Prosecute BRISBANE, Calif. / Oct 08, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Department of Justice (DOJ) has concluded... Read More

BRISBANE, Calif. / Sep 13, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on September 12, 2024, 14 new... Read More

CareDx Announces Addition of Operational and Commercial Expertise to Lead Key Strategic Initiatives Marica Grskovic Appointed Chief Strategy Officer to Lead Corporate Development BRISBANE, Calif. / Sep 12, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant... Read More

CMS Recognizes the Importance of Surveillance Testing for Early Detection of Allograft Rejection CMS to Retire Proposed Draft Policy that Would Have Restricted Coverage BRISBANE, Calif. / Aug 16, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ – today announced that the Centers for Medicare and Medicaid Services (CMS) has announced its plan to retire a draft LCD that would have restricted... Read More

BRISBANE, Calif. / Jul 31, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Reported total revenue of $92.3 million, an increase of 31% year-over-year. Grew Testing Services volume to 43,700 tests, an increase of 17% year-over-year. Reported GAAP net loss of $1.4 million, non-GAAP net income of $13.6... Read More

BRISBANE, Calif. / Jul 16, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. Company management will host a... Read More

Surveillance Monitoring with Both AlloSure Kidney and the AlloView AI-Enabled Risk Prediction Model Improves the Detection of All Types of Allograft Rejection AlloSure Kidney Detected Subclinical Rejection in Clinically Stable Patients and AlloSure Kidney dd-cfDNA Levels were Elevated Prior to Biopsy Proven Rejection in an Analysis of Patients Receiving Consecutive Biopsies AlloSure dd-cfDNA Levels Declined in Response to... Read More

AI-Derived AlloView Results Correlate with Presence and Type of Biopsy Proven Kidney Rejection Longitudinal Monitoring with AlloSure Kidney Enables Earlier Identification of Graft Injury and Assessment of Rejection Treatment KOAR Data Show Kidney Biopsies Informed by AlloSure Detect More Acute Rejection than Biopsies Based on Traditional Indications BRISBANE, Calif. / May 30, 2024 / Business Wire / CareDx, Inc. (Nasdaq:... Read More

CareDx Reiterates Position that it Does Not Infringe Natera’s ‘544 Patent Injunction Motion has No Impact on CareDx’s Business or Patient and Clinician Access to AlloSure or AlloMap BRISBANE, Calif. / May 29, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant... Read More

BRISBANE, Calif. / May 29, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences. CareDx’s management is scheduled... Read More

HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular Rejection Cardiologists Performed the Fewest Biopsies After Dual Negative HeartCare Results Compared to Single or Dual Positive Results Two-Year Clinical Outcomes Data Demonstrate Excellent Survival and Allograft Function BRISBANE, Calif. / May 16, 2024 / Business Wire / CareDx, Inc. ( Nasdaq: CDNA) – The Transplant Company™ – a leading... Read More

Raises 2024 Revenue Guidance to $274 to $282 Million BRISBANE, Calif. / May 09, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Reported first quarter revenue of $72.0 million. Revenue for Testing Services of $53.8 million, an increase of 15% as compared to the fourth quarter 2023. Grew testing services patients... Read More

BRISBANE, Calif. / May 03, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on April 19, 2024, 17 new... Read More

BRISBANE, Calif. / Apr 29, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will host a... Read More

BRISBANE, Calif. / Apr 19, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx’s common stock... Read More

BRISBANE, Calif. / Apr 16, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company’s Board of Directors, effective... Read More

Late-Breaking Abstract Presentation to Showcase Results from SHORE Registry Highlighting Benefits of Surveillance with HeartCare BRISBANE, Calif. / Apr 09, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and... Read More

BRISBANE, Calif. / Mar 11, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that Bryan Riggsbee joins CareDx’s Board of Directors, effective March 11, 2024. “We're pleased to... Read More

Delivered Total Revenue of $280.3 Million, Exceeding the High End of Updated Guidance for 2023 Grew Testing Services Results for the Second Quarter in a Row BRISBANE, Calif. / Feb 28, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 Highlights Reported full year revenue of $280.3 million,... Read More

BRISBANE, Calif. / Feb 27, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the company will be participating in the upcoming Raymond James & Associates’ 45th Annual... Read More

BRISBANE, Calif. / Feb 21, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28, 2024. Company... Read More

BRISBANE, Calif. / Feb 21, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) —The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it will be showcasing the breadth of its specialized digital solutions and the latest advancements in... Read More

CareDx Found to Have Not Infringed on Patent ‘180 CareDx Intends to Seek Judicial Review of Decision and Monetary Damages on Patent ‘544 No Impact to Patient or Physician Access to AlloSure or AlloMap Testing BRISBANE, Calif. / Jan 26, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare... Read More

CareDx Symposium to Highlight New Real-World Use Cases Using its Testing and Digital Solutions for Improved Patient Risk Management BRISBANE, Calif. / Jan 11, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading... Read More

BRISBANE, Calif. / Jan 09, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported preliminary financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 Highlights Full... Read More

CareDx Expands Reach of its Transplant Pharmacy Services by Offering NFT Patients Help in Navigating the Complexity of Immunosuppression Medications and Adherence BRISBANE, Calif. / Dec 19, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers... Read More

BRISBANE, Calif. / Nov 08, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today reported financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Highlights Reported revenue of $67.2 million, an increase of... Read More

BRISBANE, Calif. / Nov 02, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the third quarter 2023 after market close on Wednesday, November 8 th , 2023. Company management will host... Read More

Board Establishes Office of the CEO, Conducts Search for Successor Raises 2023 Revenue Guidance BRISBANE, Calif. / Nov 01, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced today that Dr. Reginald Seeto will be stepping down... Read More

Demonstrates Breadth of Offerings for HLA Laboratories and Validation of AlloSeq HCT BRISBANE, Calif. / Oct 17, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 49th annual meeting of the... Read More

Decision has No Impact on CareDx’s Ability to Continue Providing AlloSure® nor Commitment to Transplant Innovation CareDx Believes Decision Applies Equally to Other Diagnostics Patents, including Natera’s Transplant Diagnostic Patents BRISBANE, Calif. / Oct 03, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically... Read More

BRISBANE, Calif. / Sep 19, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the 2023 Cantor Global Healthcare Conference. CareDx’s management is scheduled to present at... Read More

BRISBANE, Calif. / Aug 31, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the H.C. Wainwright 25 th Annual Global Investment Conference. CareDx’s management is scheduled... Read More

Conference Underscores CareDx’s Commitment to Improving Entire Transplant Patient Journey BRISBANE, Calif. / Aug 17, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its second annual digital health user conference, the... Read More

CareDx Welcomes Open Process to Gain Transplant Community Feedback on Critical Medicare Coverage Decision BRISBANE, Calif. / Aug 11, 2023 / Business Wire / CareDx, Inc. ( Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today commented on the issuance of... Read More

BRISBANE, Calif. / Aug 08, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Highlights and Other Recent Updates CareDx received the... Read More

BRISBANE, Calif. / Aug 07, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the United States District Court for the District of Delaware (the “District Court”) issued an injunction prohibiting Natera (Nasdaq: NTRA)... Read More

BRISBANE, Calif. / Aug 03, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2023 after market close on Tuesday, August 8 th , 2023. Company management will host a... Read More

HeartCare Combines Testing Using Both AlloMap Gene Expression Profiling and AlloSure Donor-Derived Cell-Free DNA BRISBANE, Calif. / Aug 02, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced Medicare coverage... Read More

MediGO Platform Aims to Improve Access to Donated Organs and Shorten Transplant Wait Times Acquisition Expands CareDx Digital Health Portfolio and Establishes Footprint in OPO Market BRISBANE, Calif. / Jul 25, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for... Read More

Decision Reinforces CareDx Commitment to Patients by Defending Clinical Data Integrity and Reaffirms that Natera Intentionally Falsely Advertised to the Transplant Community BRISBANE, Calif. / Jul 17, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and... Read More

AlloSure Lung Represents First dd-cfDNA Approved by Medicare for Lung Transplant Patients BRISBANE, Calif. / Jul 11, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx’s AlloSure® Lung donor-derived cell-free... Read More

Record Number of 65 Abstracts Showcasing CareDx Innovation Including Data Showing Clinical Utility of AlloSure Kidney to Guide Immunosuppression Management Experts Review Advancements in Artificial Intelligence and Molecular Diagnostics During CareDx Symposium BRISBANE, Calif. / Jun 01, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of... Read More

BRISBANE, Calif. / Jun 01, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences. CareDx’s management is scheduled to present at the Jefferies... Read More

CareDx Symposium Addresses Barriers in Access to Transplantation BRISBANE, Calif. / May 16, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will showcase its digital health portfolio and host a... Read More

BRISBANE, Calif. / May 10, 2023 / Business Wire / CareDx, Inc . (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Delivered record number of patient test results for... Read More

BRISBANE, Calif. / May 08, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10, 2023. Company management will host a... Read More

Posters and Symposium Highlight Utility of AlloSeq for HLA Typing, Organ Transplant Monitoring and Hematopoietic Stem Cell Monitoring BRISBANE, Calif. / Apr 25, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today... Read More

Data Highlights the Value of HeartCare and AlloSure Lung in Clinical Practice Leading Experts Present Latest Advancements in Heart and Lung Transplantation During CareDx Symposia BRISBANE, Calif. / Apr 19, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for... Read More

CareDx Receives Award for Introducing RemoTraC During Pandemic and Sponsoring the Honor the Gift Coalition for Successful Passage of the Immuno Bill BRISBANE, Calif. / Apr 06, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –... Read More

CareDx to Host Symposium Featuring the Latest Developments in Pediatric Transplant Care BRISBANE, Calif. / Mar 23, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its gold-level sponsorship and participation... Read More

BRISBANE, Calif. / Mar 06, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the Raymond James & Associates’ 44 th Annual Institutional Investors Conference. CareDx’s management is... Read More

BRISBANE, Calif. / Mar 01, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced that it is sponsoring the National Kidney Foundation (NKF) Annual Kidney Patient Summit taking place on Capitol Hill on March 1-2,... Read More

BRISBANE, Calif. / Feb 27, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved full year revenue of $321.8 million,... Read More

BRISBANE, Calif. / Feb 22, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced that it is showcasing the clinical value of multimodality and artificial intelligence innovation at the annual American Society of... Read More

BRISBANE, Calif. / Feb 16, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced that it will be presenting its latest solutions to support the cellular transplant and therapy ecosystem at the 2023 Tandem... Read More

CareDx Showcase Latest Innovations in Pre- and Post-Transplant Patient Care CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced its leading participation and top spot, for the fourth consecutive year, as a Distinguished Founder’s... Read More

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported preliminary financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter Highlights Delivered record revenues; expected to be between $81.9 million to $82.2... Read More

ISHLT Guidelines Recommend Earlier Use of AlloMap Heart Starting 2 Months Post-Transplant Based on Strength of Clinical Studies ISHLT Guidelines Recommend Remote Use of GEP and dd-cfDNA Heart Transplant Surveillance, as in HeartCare, May be Used to Reduce the Need for Biopsies and Hospital Visits CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically... Read More